BRUCHER, Björn LDM, Gary LYMAN, Richard van HILLEGERSBERG, Raphael E. POLLOCK, Florian LORDICK, Han-Kwang YANG, Toshikazu USHIJIMA, Khay-Guan YEOH, Tomáš SKŘIČKA, Wojciech POLKOWSKI, Grzegorz WALLNER, Vic VERWAAL, Alfredo GAROFALO, Domenico D´UGO, Franco ROVIELLO, Hans-Ulrich STEINAU, Timothy J. WALLACE, Martin DAUMER, Nitah MAIHLE, Thomas J. REID, Michel DUCREUX, Yuko KITAGAWA, Alexander KNUTH, Bruno ZILBERSTEIN, Scott R. STEELE and Ijaz S. JAMALL. Imagine a world without cancer. BMC Cancer. London: BioMed Central, 2014, vol. 14, No 186, p. 1-8. ISSN 1471-2407. Available from: https://dx.doi.org/10.1186/1471-2407-14-186.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Imagine a world without cancer
Authors BRUCHER, Björn LDM (840 United States of America), Gary LYMAN (840 United States of America), Richard van HILLEGERSBERG (528 Netherlands), Raphael E. POLLOCK (840 United States of America), Florian LORDICK (276 Germany), Han-Kwang YANG (410 Republic of Korea), Toshikazu USHIJIMA (392 Japan), Khay-Guan YEOH (702 Singapore), Tomáš SKŘIČKA (203 Czech Republic, guarantor, belonging to the institution), Wojciech POLKOWSKI (616 Poland), Grzegorz WALLNER (616 Poland), Vic VERWAAL (528 Netherlands), Alfredo GAROFALO (380 Italy), Domenico D´UGO (380 Italy), Franco ROVIELLO (380 Italy), Hans-Ulrich STEINAU (276 Germany), Timothy J. WALLACE (840 United States of America), Martin DAUMER (276 Germany), Nitah MAIHLE (840 United States of America), Thomas J. REID (840 United States of America), Michel DUCREUX (250 France), Yuko KITAGAWA (392 Japan), Alexander KNUTH (634 Qatar), Bruno ZILBERSTEIN (76 Brazil), Scott R. STEELE (840 United States of America) and Ijaz S. JAMALL (840 United States of America).
Edition BMC Cancer, London, BioMed Central, 2014, 1471-2407.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.362
RIV identification code RIV/00216224:14110/14:00077732
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1186/1471-2407-14-186
UT WoS 000333422100002
Keywords in English Cancer; Carcinogenesis; Multimodal therapy; Cancer classification; Personalized anticancer therapy; Individualized anticancer therapy
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 11/12/2014 15:20.
Abstract
Since the "War on Cancer" was declared in 1971, the United States alone has expended some $300 billion on research, with a heavy focus on the role of genomics in anticancer therapy. Voluminous data have been collected and analyzed. However, in hindsight, any achievements made have not been realized in clinical practice in terms of overall survival or quality of life extended. This might be justified because cancer is not one disease but a conglomeration of multiple diseases, with widespread heterogeneity even within a single tumor type. Discussion: Only a few types of cancer have been described that are associated with one major signaling pathway. This enabled the initial successful deployment of targeted therapy for such cancers. However, soon after this targeted approach was initiated, it was subverted as cancer cells learned and reacted to the initial treatments, oftentimes rendering the treatment less effective or even completely ineffective. During the past 30 plus years, the cancer classification used had, as its primary aim, the facilitation of communication and the exchange of information amongst those caring for cancer patients with the end goal of establishing a standardized approach for the diagnosis and treatment of cancers. This approach should be modified based on the recent research to affect a change from a service-based to an outcome-based approach. The vision of achieving long-term control and/or eradicating or curing cancer is far from being realized, but not impossible. In order to meet the challenges in getting there, any newly proposed anticancer strategy must integrate a personalized treatment outcome approach. This concept is predicated on tumor-and patient-associated variables, combined with an individualized response assessment strategy for therapy modification as suggested by the patient's own results. As combined strategies may be outcome-orientated and integrate tumor-, patient-as well as cancer-preventive variables, this approach is likely to result in an optimized anticancer strategy. Summary: Herein, we introduce such an anticancer strategy for all cancer patients, experts, and organizations: Imagine a World without Cancer.
PrintDisplayed: 9/9/2024 02:19